Hints and tips:
...As chief executive of Alere, a US medical diagnostics company, Mr Nawana earned a $8.6m pay package in 2016 and $11.1m in 2015. At S&N, he earned $2.8m for the seven months of 2018....
...He led the turnround of medical diagnostics maker Alere before overseeing its sale to Abbott in 2017 for $7.8bn including debt....
...Namal Nawana has quit as chief executive of Smith & Nephew after 18 months because the UK medical devices company could not meet his pay demands....
...Mr Nawana, who earned $11.1m in 2015 at US diagnostics group Alere, wanted more than the $6m he is due to make this year if he hits all his targets....
...And Namal Nawana, formerly of New Jersey’s Johnson & Johnson and Alere of Massachusetts, is leaving Watford-based medical group Smith & Nephew over his pay demands....
...When Namal Nawana was wooed to take the top job at Smith & Nephew, he took a hard look at the venerable UK medical devices company and found both a puzzle and an opportunity....
...and his current role at the FTSE 100 medical devices maker, which he joined last May....
...Abbott Laboratories, the US medical device company, has revised the terms of its planned $5bn-plus takeover of smaller rival Alere, ending a protracted legal battle between the two companies....
...Board members at the medical devices maker have discussed moving the company’s share listing to the US, partly to escape the UK’s stricter attitude towards executive pay....
...The FTSE 100 company said on Wednesday that Olivier Bohuon would step down next month after seven years as chief executive and would be replaced by Mr Nawana, who headed the medical diagnostics company Alere...
...Progress is being made, and Dr Domingo points to a product launched by Alere, a US medical device company that was bought by rival Abbott last year....
...Namal Nawana, who sold diagnostics company Alere to Abbott for $5.3bn last year, has experience of both turnrounds and deals....
...Now, the company has said Olivier Bohuon will step down as CEO next month after a seven-year tenure, to be replaced by Namal Nawana, who was previously CEO of medical dignostics company Alere....
...He most recently headed the medical diagnostics company Alere, where he oversaw a contentious takeover by Abbott Laboratories last year. Nawana also spent 15 years at Johnson & Johnson....
...Just 10 months after Abbott Laboratories announced with much fanfare its $5.8bn acquisition of diagnostic test provider Alere, the Chicago-based medical device maker is looking to walk away....
...Investors will be looking out for updates on the company’s products that recently won approval and for updates on the Alere deal....
...For medical device companies Abbott Laboratories and Alere, the signing of their deal was just the beginning of the contretemps. Abbott’s shareholders should be asking why....
...Also on Monday, medical device company Stryker agreed to buy Sage, which makes care products, for $2.8bn....
...Alere for £235m in 2011....
...Abbott will pay Alere shareholders $56 a share to take control of a company that specialises in medical tests for infectious diseases, such as HIV, tuberculosis, malaria and dengue....
...Aetna’s bottom line received a lift from a reduction in medical care spending....
...Companies can play an important role in this, argues Jennifer Lovejoy, senior vice-president of clinical and quality support at US-based Alere Wellbeing, which provides tobacco cessation and weight loss...
...ensure that the rise of drug-resistant strains cease, is to make sure patients have access to timely and accurate diagnosis,” says Renuka Gadde, vice-president of global health at Becton Dickinson, the medical...
...Alere – known as Inverness Medical Innovations until last year – on Thursday said Axis-Shield’s predictions for the success of Afinion in the US were “predicated on achieving important regulatory milestones...
...But Alere – known as Inverness Medical Innovations until last year – said that Axis-Shield’s predictions for the success of Afinion in the US were “predicated on achieving important regulatory milestones...
International Edition